Based on the Eli Lilly and Company stock forecast from 0 analysts, the average analyst target price for Eli Lilly and Company is not available over the next 12 months. Eli Lilly and Company’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Eli Lilly and Company is Slightly Bullish , which is based on 10 positive signals and 8 negative signals. At the last closing, Eli Lilly and Company’s stock price was EUR 750.60. Eli Lilly and Company’s stock price has changed by +1.32% over the past week, +5.64% over the past month and +45.18% over the last year.
No recent analyst target price found for Eli Lilly and Company
No recent average analyst rating found for Eli Lilly and Company
Company Overview Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It operates Lilly Seaport Innovation Center (LSC), a research and development facility in the Boston Seaport to advancing Lilly's efforts in RNA and DNA-based therapies as well as discovering new drug targets to create life-changing medicines across several disease states, including diabetes, obesity, cardiovascular diseases, neurodegeneration, and chronic pain. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; and Chugai Pharmaceutical Co., Ltd, as well as development collaboration with Eli Lilly and Company for developing QIAstat-Dx IVD panel, for the detection of various APOE genotypes. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. Read Less
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 7...Read More
Frequently Asked Questions About Eli Lilly and Company (LLY:XETRA) Stock
Stock Target Advisor's fundamental analysis for Eli Lilly and Company's stock is Slightly Bullish .
LLY:XETRA stock's dividend yield is 0.62%.
Our analysis grades LLY:XETRA stock's dividend yield at F. This means that LLY:XETRA stock's dividend yield is above 15% of the stocks in the Drug Manufacturers - General sector in the XETRA exchange.
Based on this LLY:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on LLY:XETRA's stock to indicate what its average analyst target is.
LLY:XETRA stock's Price/Earning ratio is 90.93.
Our analysis grades LLY:XETRA stock's Price / Earning ratio at F. This means that LLY:XETRA stock's Price/Earning ratio is above 86% of the stocks in the Drug Manufacturers - General sector in the XETRA exchange.
Based on this LLY:XETRA may be a overvalued for its sector.
The last closing price of LLY:XETRA's stock was EUR 750.60.
The most recent market capitalization for LLY:XETRA is EUR 713.88B.
Unfortunately we do not have enough analyst data on LLY:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eli Lilly and Company's stock.
As per our most recent records Eli Lilly and Company has 43,000 Employees.
Eli Lilly and Company's registered address is Lilly Corporate Center, Indianapolis, IN, United States, 46285.
You can get more information about it from Eli Lilly and Company's website at https://www.lilly.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior capital utilization
The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
High dividend returns
The stock has outperformed its sector peers on average annual dividend returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile. This can be a good buy, especially if it is outperforming on total return basis , for investors seeking high income yields.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median total returns
The company has under performed its peers on annual average total returns in the past 5 years.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Eli Lilly and Company (LLY:XETRA) Stock
Stock Target Advisor's fundamental analysis for Eli Lilly and Company's stock is Slightly Bullish .
LLY:XETRA stock's dividend yield is 0.62%.
Our analysis grades LLY:XETRA stock's dividend yield at F. This means that LLY:XETRA stock's dividend yield is above 15% of the stocks in the Drug Manufacturers - General sector in the XETRA exchange.
Based on this LLY:XETRA may be a poor dividend stock for its sector.
Unfortunately we do not have enough data on LLY:XETRA's stock to indicate what its average analyst target is.
LLY:XETRA stock's Price/Earning ratio is 90.93.
Our analysis grades LLY:XETRA stock's Price / Earning ratio at F. This means that LLY:XETRA stock's Price/Earning ratio is above 86% of the stocks in the Drug Manufacturers - General sector in the XETRA exchange.
Based on this LLY:XETRA may be a overvalued for its sector.
The last closing price of LLY:XETRA's stock was EUR 750.60.
The most recent market capitalization for LLY:XETRA is EUR 713.88B.
Unfortunately we do not have enough analyst data on LLY:XETRA's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Eli Lilly and Company's stock.
As per our most recent records Eli Lilly and Company has 43,000 Employees.
Eli Lilly and Company's registered address is Lilly Corporate Center, Indianapolis, IN, United States, 46285.
You can get more information about it from Eli Lilly and Company's website at https://www.lilly.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for LLY:XETRA !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
